Immatics presenting Allogeneic Cell Therapy Summit 2020
Oct 27, 2020 from 1:30 PM to 2:00 PM EDT
Join us at the Allogeneic Cell Therapy Summit which brings together both immunotherapy and regenerative medicine leaders. The virtual event is focused on the clinical and commercial development of engineered allogeneic cell therapies with improved manufacturing and commercialization to benefit patients in need.
Tuesday, October 27, 1.30pm EST
Session: Translation - Outlining Techniques to Increase Persistence & Overcome Rejection
Presentation: ACTallo®: Off-the-Shelf γδ T Cells Engineered Against Novel Tumor Targets
- γδ T cells as the ideal solution for allogeneic therapy, due to their intrinsic antitumor activity, inherent ability to infiltrate tumors and MHC independent TCR unlikely to cause GvHD
- ACTallo as a leverage to the intrinsic properties of these cells with the addition of a tumor-specific TCR, in a cGMP-compliant process
- Discussion on the latest platform development data
Speaker: Melinda Mata, Senior Scientist, Immatics
We are looking forward to e-meeting you!
For more information visit the event's homepage: Allogeneic Cell Therapy Summit 2020